Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: Further analyses of the Austrian immunoglobulin in MS study

Multiple Sclerosis

Volumn 3, Issue 2, 1997, Pages 137-141

  Fazekas, Franz ^a   Deisenhammer, Florian ^b   Strasser Fuchs, Siegrid ^a   Nahler, Gerhard ^c   Mamoli, Bruno ^d  

^a UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c Clinical Investigation Support GmbH UCo KG   (Austria)

^d Hospital Rosenhügel   (Austria)

Author keywords

Baseline disability; Intravenous immunoglobulin; Relapsing remitting MS; Remyelination; Time course of treatment effects

Indexed keywords

IMMUNOGLOBULIN;

ADOLESCENT; ADULT; AGED; AUSTRIA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETERIORATION; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION;

EID: 0030799818     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/135245859700300214     Document Type: Conference Paper

References (26)

1. Hafler DA, Weiner HL. MS. a CNS and systemic autoimmune disease. Immunol Today 1989; 10: 104-107.
2. Martin R, McFarland HF. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit Rev Clin Lab Sci 1995; 32: 121-182.
3. Giovannoni G, Hartung H-P. The immunopathogenesis of multiple sclerosis and Guillain-Barré syndrome. Curr Opin Neurol 1996; 9: 165-177.
4. Van Der Mèche FGA, Schmitz PIM, and the Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326: 1123-1129.
5. Vermeulen M et al. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyolinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993; 56: 36-39.
6. Dalakas MC et al. A controlled trial of high dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993-2000.
7. Rothfelder U, Neu I, Pelka R. Therapy of multiple sclerosis with immunoglobulin G. MMW Munch Med Wochenschr 1982; 124: 74-78.
8. Schuller E, Govaerts A. First results of immunotherapy with immunoglobulin G in multiple sclerosis patients. Eur Neurol 1983; 22: 205-212.
9. Soukop W, Tschabitscher H. Gamma globulin therapy in multiple sclerosis. Theoretical considerations and initial clinical experiences with 7S immunoglobulins in MS therapy. Wien Med Wochenschr 1986; 130: 477-480.
10. Achiron A et al. Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis. Arch Neurol 1992; 49: 1233-1236.
11. Achiron A et al. Intravenous gammaglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis: delineation of usage and mode of action. J Neurol Neurosurg Psychiatry 1994; 57: S57-61.
12. Fazekas F et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997; 349: 589-593.
13. Poser CM et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
14. Hauser SL. Multiple sclerosis and other demyelinating diseases. In: Isselbacker KJ et al. (eds.). Harrison's Principles of Internal Medicine, vol 2. McGraw-Hill: New York 1994; pp 2287-2295.
15. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
16. Bornstein MB et al. A pilot trial of COP 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987; 317: 408-414.
17. Rodriguez M, Miller DJ, Lennon VA. Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology 1996; 46: 538-545.
18. van Engelen BGM et al. Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Ann Neurol 1992; 32: 835-836.
19. Tenser RB, Hay KA, Aberg JA. Immunoglobulin G immunosuppression of multiple sclerosis. Suppression of all three major lymphocyte subsets. Arch Neurol 1993; 50: 417-420.
20. Jungi TW et al. Effect of IgG for intravenous use on Fc receptor mediated phagocytosis by human monocytes. Clin Exp Immunol 1990; 82: 163-169.
21. Frank MM, Basta M, Fries LF. The effect of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunpathol 1992; 62: S82-86.
22. Anderson UG, Bjork L, Skansen-Saphir U, Anderson JP. Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunol 1993; 79: 211-216.
23. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-1285.
24. Johnson KP et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-1276.
25. Noseworthy JH, O'Brien PC, van Engelen BGM, Rodriguez M. Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial. J Neurol Neurosurg Psychiatry 1994; 57: S11-14.
26. Soelberg Sörensen P et al. A double-blind cross-over trial of intravenous immunoglobulin in multiple sclerosis: preliminary results. Europ J Neurol 1996; 3: S34-35 (abstract).